These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30549085)

  • 41. Incentives and disincentives to drug innovation: evidence from recent literature.
    Lee Mendoza R
    J Med Econ; 2019 Aug; 22(8):713-721. PubMed ID: 31038374
    [No Abstract]   [Full Text] [Related]  

  • 42. Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word.
    Hawkins N; Scott DA
    Health Econ; 2011 Jun; 20(6):688-98. PubMed ID: 20568075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic challenges of using innovative medical devices in major public health pathologies: Example of acute ischemic stroke management by mechanical thrombectomy.
    Nativel F; Detraz L; Mauduit N; Riche VP; Desal H; Grimandi G
    Rev Epidemiol Sante Publique; 2019 Nov; 67(6):361-368. PubMed ID: 31662284
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug Policy in Romania.
    Radu CP; Pana BC; Furtunescu FL
    Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of economic evaluation in the pricing and reimbursement of medicines.
    Drummond M; Jönsson B; Rutten F
    Health Policy; 1997 Jun; 40(3):199-215. PubMed ID: 10168752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
    Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
    Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
    Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
    Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor.
    Gandjour A; Gafni A; Schlander M
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):123-9. PubMed ID: 24354766
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FACTORS INFLUENCING REIMBURSEMENT OF MEDICAL DEVICES IN FRANCE.
    Loge P; Delalande F; Reymond MC; Germain S
    Int J Technol Assess Health Care; 2015; 31(6):399-406. PubMed ID: 26868190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry.
    Badora K; Caban A; Rémuzat C; Dussart C; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1381544. PubMed ID: 29081924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulation, coverage, and reimbursement of medical technologies.
    McGivney WT; Hendee WR
    Int J Radiat Oncol Biol Phys; 1990 Mar; 18(3):697-700. PubMed ID: 2318704
    [TBL] [Abstract][Full Text] [Related]  

  • 53. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology--part 3: payment.
    Raab GG; Parr DH
    J Am Coll Radiol; 2006 Nov; 3(11):842-50. PubMed ID: 17412183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug Policy in Greece.
    Yfantopoulos JN; Chantzaras A
    Value Health Reg Issues; 2018 Sep; 16():66-73. PubMed ID: 30195093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Average wholesale price for prescription drugs: is there a more appropriate pricing mechanism?
    Gencarelli DM
    NHPF Issue Brief; 2002 Jun; (775):1-19. PubMed ID: 12083159
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The End of the International Reference Pricing System?
    Persson U; Jönsson B
    Appl Health Econ Health Policy; 2016 Feb; 14(1):1-8. PubMed ID: 26112982
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
    Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
    Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain.
    Campillo-Artero C; Garcia-Armesto S; Bernal-Delgado E
    Health Policy; 2016 Sep; 120(9):975-81. PubMed ID: 27460522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.